Evidence map›Paper›PMID 39931993›Full record

ArticleCurrent drug safety2025

Extreme and Severe Systemic Pain Caused by Rifampicin: A Case Report of a Rare Allergic Reaction.

Tong-Xin Li, Yan-Mei Xiong, Wen-Wan Gao, Bohao Jiang, Ying He, Shiyan He, Lei Xu, Song Yang

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Current drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tong-Xin LiCentral Laboratory, Chongqing Public Health Medical Center, Chongqing, 400036 China.
Yan-Mei XiongDepartment of Comprehensive Internal Medicine, Chongqing Public Health Medical Center, Chongqing, 400036, China.
Wen-Wan GaoCentral Laboratory, Chongqing Public Health Medical Center, Chongqing, 400036 China.
Bohao JiangDepartment of Urology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001 China.
Ying HeCentral Laboratory, Chongqing Public Health Medical Center, Chongqing, 400036 China.
Shiyan HeDepartment of Pathogenic Biology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Lei XuDepartment of Pathogenic Biology, College of Basic Medicine, Chongqing Medical University, Chongqing, 400016, China.
Song YangDepartment of Comprehensive Internal Medicine, Chongqing Public Health Medical Center, Chongqing, 400036, China.

Funding

Chongqing Medical Scientific Research Project (Joint Project of Chongqing Health Commission and Science and Technology Bureau) 2024MSXM061
6 · The paper itself

Abstract

backgroundRifampicin is a first-line anti-tuberculosis drug, but it may cause severe allergic adverse reactions. CASE PRESENTATION: This case report describes an unusual and severe adverse reaction to rifampicin in a 53-year-old male patient with pulmonary tuberculosis. The patient developed intense systemic pain within 4 hours of rifampicin administration, affecting multiple organs and joints, without typical allergic manifestations, such as fever or rash. The pain progressively worsened over three consecutive days of treatment, reaching its peak intensity (NRS score 8/10) on the third day with pain duration extending from 3 to 8 hours. The severe pain was characterized as sharp and burning in nature, significantly impacting the patient's daily activities and mobility. A subsequent rifampicin challenge test (single dose 0.45g) confirmed the causal relationship by reproducing identical severe pain symptoms. The Naranjo adverse drug reaction probability scale yielded a score of 7, indicating a "probable" causal relationship. Notably, the patient exhibited underlying autoimmune abnormalities (positive ANA and elevated ESR), which may have contributed to the severity of the reaction through enhanced inflammatory responses and altered pain mechanisms. The symptoms completely resolved upon rifampicin discontinuation, and alternative treatment with levofloxacin proved successful with no pain recurrence during the fourmonth follow-up period.

conclusionThis case highlights a previously unreported presentation of rifampicin hypersensitivity and emphasizes the importance of careful risk assessment in patients with autoimmune features before initiating rifampicin therapy.

Indexed as

Antibiotics, AntitubercularDrug HypersensitivityPainRifampinHumansMaleMiddle AgedSeverity of Illness IndexTuberculosis, PulmonaryAntibiotics, AntitubercularRifampinAdverse drug reaction reporting systemsarthralgiadrug hypersensitivitypharmacovigilancerifampintuberculosis.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.